瓣中瓣经导管主动脉瓣置换术后永久起搏器植入:VIVID注册研究
基于多中心VIVID注册研究,纳入2007至2020年1,987例既往无起搏器、接受瓣中瓣经导管主动脉瓣置换术的患者,围术期永久起搏器植入率为6.4%,使用新一代瓣膜时发生率显著降低;起搏器植入与随访期死亡风险呈升高趋势。
要点
- 瓣中瓣经导管主动脉瓣置换术后围术期永久起搏器植入率为6.4%。
- 使用新一代瓣膜者起搏器植入率低于早期瓣膜(4.7% vs 7.4%)。
- 起搏器植入患者随访期死亡风险呈升高趋势,30天死亡率无显著差异。
核心结论
- 在当代大规模瓣中瓣经导管主动脉瓣置换术人群中,围术期永久起搏器植入率相对较低,且随新一代瓣膜系统的使用而下降。
- 瓣中瓣经导管主动脉瓣置换术后永久起搏器植入与随访期死亡风险升高呈趋势相关。
研究设计与样本
- 多中心VIVID注册研究,纳入2007至2020年接受瓣中瓣经导管主动脉瓣置换术且既往无永久起搏器植入的1,987例患者。
- 按是否需围术期永久起搏器植入分析院内及晚期结局,中位随访13个月(四分位距3至41个月)。
- 除CoreValve、Cribier-Edwards、Sapien和Sapien XT外的瓣膜均视为新一代经导管心脏瓣膜。
主要发现
- 128例(6.4%)在经导管主动脉瓣置换术后植入永久起搏器。
- 新一代瓣膜起搏器植入率低于早期瓣膜(4.7% vs 7.4%;p=0.017),主要与Evolut R/Pro较CoreValve起搏器植入率降低有关(3.7% vs 9.0%;p=0.002)。
- 新一代球囊扩张与自膨胀瓣膜之间起搏器植入率无显著差异(6.1% vs 3.9%;p=0.18)。
- 多变量分析中,年龄较大(每增加1岁OR 1.05;95%CI 1.02至1.07;p=0.001)、瓣膜尺寸较大(OR 1.10;95%CI 1.01至1.20;p=0.02)及既往右束支传导阻滞(OR 2.04;95%CI 1.00至4.17;p=0.05)与起搏器植入风险增加相关。
- 起搏器组与无起搏器组30天死亡率无差异(4.7% vs 2.7%;p=0.19),但起搏器组随访期死亡风险呈升高趋势(HR 1.39;95%CI 1.02至1.91;p=0.04;校正年龄差异后p=0.08)。
临床怎么用
- 瓣中瓣经导管主动脉瓣置换术前应评估年龄、瓣膜尺寸及既往右束支传导阻滞等起搏器植入风险因素。
- 优先选用新一代瓣膜系统可能有助于降低围术期永久起搏器植入率。
- 对术后植入起搏器的患者应关注随访期死亡风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). OBJECTIVES: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. METHODS: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. RESULTS: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). CONCLUSIONS: In a contemporary large series of ViV-TAVR patients, the rate of periprocedural PPI was relatively low, and its incidence decreased with the use of new-generation THV systems. PPI following ViV-TAVR was associated with a trend toward increased mortality at follow-up.
引用
- Alperi A, Rodés-Cabau J, Simonato M, et al. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry. J Am Coll Cardiol. 2021. PMID: 33958122. doi:10.1016/j.jacc.2021.03.228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。